companies / inventivapharma-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 216,000,000216.0M | ○ |
|---|---|---|
| founded | 2012 | |
| hq | Daix, France | |
| industry | unknown | |
| stage | series-b+ |
Inventiva Pharma is a French clinical-stage biopharma focused on lanifibranor, an oral pan-PPAR agonist for metabolic dysfunction-associated steatohepatitis. It targets MASH patients with advanced fibrosis lacking oral options. The Phase 3 NATiV3 trial of 1,000+ patients is expected to read out in H2 2026.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-11-15 | seed | 160,920,000160.9M | null | ○ |
Apache HTTP Server, Modernizr, Yoast SEO 27.5, Google Analytics, Google Tag Manager, jQuery Migrate 3.4.1, particles.js, Polylang, DoubleClick Floodlight, CookieYes 3.4.2, OneSignal, OWL Carousel
| fact | status | src |
|---|---|---|
| Seed, $160.9M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |